These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35959915)

  • 1. Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis.
    Feng W; Hu Y; Zhang C; Shi H; Zhang P; Yang Y; Chen S; Cui W; Cui D
    Bioengineered; 2022 Jun; 13(6):14719-14729. PubMed ID: 35959915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.
    Ye X; Bo X; Hu X; Cui H; Lu B; Shao J; Wang J
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):247-255. PubMed ID: 27484048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
    Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
    J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies for Graves' ophthalmopathy: a network meta-analysis.
    Zhou X; Zhou D; Wang J; Chen G
    Br J Ophthalmol; 2020 Apr; 104(4):551-556. PubMed ID: 31272958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
    Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
    Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous glucocorticoids therapy in the treatment of Graves' ophthalmopathy: a systematic review and Meta-analysis.
    Zhao LQ; Yu DY; Cheng JW
    Int J Ophthalmol; 2019; 12(7):1177-1186. PubMed ID: 31341811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.
    Riedl M; Kuhn A; Krämer I; Kolbe E; Kahaly GJ
    J Endocrinol Invest; 2016 Jun; 39(6):687-94. PubMed ID: 26886940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.
    Rajabi MT; Rafizadeh SM; Mohammadi A; Eshraghi B; Mohammadi N; Hosseini SS; Rajabi MB; Keshmirshekan MM; Shahriari M; Poursayed Lazarjani SZ; Parandin MM
    Front Med (Lausanne); 2022; 9():788228. PubMed ID: 35223896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients.
    Li LF; Xue JL; Guan L; Su FF; Wang H; Zhang DF
    Front Endocrinol (Lausanne); 2023; 14():1140196. PubMed ID: 37025403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves' Orbitopathy.
    Jia J; Dong J; Deng L
    Front Pharmacol; 2022; 13():785757. PubMed ID: 35559245
    [No Abstract]   [Full Text] [Related]  

  • 13. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
    Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
    Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
    [No Abstract]   [Full Text] [Related]  

  • 14. Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis.
    Mou P; Jiang LH; Zhang Y; Li YZ; Lou H; Zeng CC; Wang QH; Cheng JW; Wei RL
    PLoS One; 2015; 10(10):e0139544. PubMed ID: 26469187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined glucocorticoids and cyclophosphamide in the treatment of Graves' ophthalmopathy: a systematic review and meta-analysis.
    Xiang Q; Yang M; Luo W; Cao Y; Shuai S; Wei X; Xiong A
    BMC Endocr Disord; 2024 Jan; 24(1):12. PubMed ID: 38273269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis.
    Chen J; Liu H; Yin W; Xu Z; Chen Z; Yiu W
    Comput Intell Neurosci; 2022; 2022():5717068. PubMed ID: 35909831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
    Genere N; Stan MN
    Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Ma X; Tang R; Luo M; Zeng Z; Shi Y; Tang B; Xiao R
    Clin Rheumatol; 2021 Aug; 40(8):3185-3193. PubMed ID: 34080081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.